4-Chloro-3-(trifluoromethyl)phenylisocyanate
4-Chloro-3-(trifluoromethyl)phenylisocyanate structure
|
Common Name | 4-Chloro-3-(trifluoromethyl)phenylisocyanate | ||
|---|---|---|---|---|
| CAS Number | 327-78-6 | Molecular Weight | 221.564 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 201.7±0.0 °C at 760 mmHg | |
| Molecular Formula | C8H3ClF3NO | Melting Point | 40-42 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 99.4±0.0 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Synthesis and inhibitory activity of thymidine analogues targeting Mycobacterium tuberculosis thymidine monophosphate kinase
Bioorg. Med. Chem. 19(24) , 7603-1, (2011) We report on Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt) inhibitory activities of a series of new 3'- and 5'-modified thymidine analogues including α- and β-derivatives. In addition, several analogues were synthesized in which the 4-oxy... |
|
|
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
Bioorg. Med. Chem. Lett. 23(13) , 3732-7, (2013) To reduce the pro-angiogenic effects of sEH inhibition, a structure-activity relationship (SAR) study was performed by incorporating structural features of the anti-angiogenic multi-kinase inhibitor sorafenib into soluble epoxide hydrolase (sEH) inhibitors. T... |
|
|
A novel p21 attenuator which is structurally related to sorafenib.
Cancer Biol. Ther. 14(3) , 278-85, (2013) p21 is a member of the cyclin kinase inhibitor family of proteins and plays pivotal roles in cellular proliferation as well as in the regulation of apoptosis, and thus has diverse functions in diseases as varied as cancer and atherosclerosis. In light of its ... |
|
|
A highly efficient methodology for 5-methyl-3-aryl-2-thiooxazolidin-4-ones using lithium perchlorate in DIPEA mediated synthesis. Khatik GL, et al.
J. Heterocycl. Chem. 47(3) , 734, (2010)
|
|
|
Extraction and determination of the Mitins sulcofuron and flucofuron from environmental river water. áM Hancock P.
Analyst 123(8) , 1669-74, (1998)
|